937046-98-5

Basic information

• Product Name: 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine
• Synonyms: 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine;4-Amino-7-bromo-pyrrolo[2...;4-AMino-7-broMo-pyrrolo[2,1-f][1,2,4]triazine;7-BroMopyrrolo[2,1-f][1,2,4]triazin-4-aMine;1. 4-AMino-7-broMo-pyrrolo[2,1-f][1,2,4]triazine;7-Bromo-pyrrolo[2,1-f][1,2,4]triazin-4-ylamine;Pyrrolo[2,1-f][1,2,4]triazin-4-amine, 7-bromo-;7-Bromopyrrolo[1,2-f][1,2,4]triazin-44-amine
• CAS NO: 937046-98-5
• Molecular Formula: C₆H₅BrN₄
• Molecular Weight: 213.0347
• Mol File: 937046-98-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 2.098 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.82±0.30(Predicted)
• CAS DataBase Reference: 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine(937046-98-5)
• EPA Substance Registry System: 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine(937046-98-5)

Safety Data

• Hazardous Substances Data: 937046-98-5(Hazardous Substances Data)

Usage

Description

7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine is a heterocyclic organic compound characterized by the presence of a bromine atom at the 7-position and an amine group at the 4-position. It features a pyrrolo[1,2-f][1,2,4]triazin core structure, which is a fused ring system consisting of a pyrrole and a triazine. This unique molecular architecture endows it with potential applications in various fields, particularly in pharmaceutical chemistry.

Uses

Used in Pharmaceutical Industry:
7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine is used as a key intermediate in the synthesis of N-heterocyclic compounds, which are essential building blocks for the development of novel pharmaceutical agents. Its unique structural features make it a valuable precursor for the creation of diverse bioactive molecules with potential therapeutic applications.
Used in Anticancer Agents:
In the field of oncology, 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine serves as a crucial component in the design and synthesis of anticancer agents. Its incorporation into the molecular structure of these compounds can potentially enhance their ability to target and inhibit cancer cells, leading to the development of more effective treatments for various types of cancer.
Used as PRMT5 Inhibitors:
7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine also finds application in the development of protein arginine methyltransferase 5 (PRMT5) inhibitors. PRMT5 is an enzyme involved in various cellular processes, including gene expression regulation and signal transduction. Inhibition of PRMT5 has been implicated in the regulation of cancer cell growth and survival, making it an attractive target for the development of novel anticancer therapies. The unique structural features of 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine can be leveraged to design potent and selective PRMT5 inhibitors, offering new avenues for cancer treatment.

InChI:InChI=1S/C6H5BrN4/c7-5-2-1-4-6(8)9-3-10-11(4)5/h1-3H,(H2,8,9,10)

Upstream product

• 159326-68-8 pyrrolo[2,1-f][1,2,4]triazin-4-amine 
• 937046-96-3 tert-butyl (2-cyano-1H-pyrrol-1-yl)carbamate 
• 1770840-43-1 7-iodopyrrolo-[2,1-f][1,2,4]-triazin-4-amine 

Downstream Products

• 937048-34-5 [3-(4-amino-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-methanol 
• 937048-40-3 4-[3-(4-amino-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 937048-10-7 tert-butyl 4-[4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl]piperazine-1-carboxylate 
• 937048-01-6 [3-(4-amino-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-benzyl]-carbamic acidtert-butyl ester 
• 939967-94-9 4-aminopyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde 
• 159326-68-8 pyrrolo[2,1-f][1,2,4]triazin-4-amine 
• 1272971-36-4 C₂₇H₂₂FN₅O₅ 
• 1273029-19-8 C₂₄H₂₈FN₆O₇P 
• 1273029-20-1 C₂₅H₂₉ClFN₆O₇P 
• 1273029-28-9 C₂₆H₃₂FN₆O₇P 
• 1273029-50-7 C₃₄H₃₂FN₅O₅ 
• 1273029-51-8 C₆₀H₅₉FN₅O₉PS 
• 1273029-52-9 C₆₇H₆₆FN₆O₉PS 
• 1273029-53-0 C₂₇H₃₄FN₆O₇PS 

Relevant articles and documents

Regioselective mono-bromination of pyrrolo[2,1-f][1,2,4]triazin-4-amine

Pyrrolo[2,1-f][1,2,4]triazin-4-amine is regioselectively brominated when treated with 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione in different solvents. The brominated product, 5,7-dibromopyrrolo[2,1-f][1,2,4]triazin-4-amine predominates when the reaction is run in dichloromethane. The subsequent debromination process utilizes lithium-bromine exchange to give the desired product 5-bromo-pyrrolo[2,1- f][1,2,4]triazin-4-amine.

Preparation method 7-bromopyrrolo [2,1-f][1, 2, 4]-thiazine -4- amine (by machine translation)

[, ] The preparation method 7 - of [2,1 - f][1, 2, 4]-(, amino - ((((((((aopipelineao :1) aminopyrrolo 2,5 - thiopyrrole I,) obtained by reacting the intermediate 1 - Boc - 1 - with the formamidine in the following step ;2) can obtain the intermediate I (II, amino-(EC 1 - Boc - 1 -) to obtain the intermediate ;3), namely, II amino-(III, aminopyrrolopyrrole - 2 2-methanonitrile hydrochloride 1 -) to form the intermediate ;4) through the reaction of the intermediates III and the bromination reagent to obtain a final product IV, of the present invention. in an acidic condition and reacting the intermediate body with the bromination reagent. to obtain a final product (4 -aminopyrrolopyridine - 4 4) intermediate, [2,1 - f][1, 2, 4] [2,1 - f][1, 2, 4] obtained by the reaction of the intermediate body with the. bromination reagent and ;5) amino- pyrrolidine. IV-amine,aminopyrroyl hydrochloride 7 . (by machine translation)

Development of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists

We describe the synthesis of quinuclidine-containing spiroimidates and their utility as α7 nicotinic acetylcholine receptor (nAChR) partial agonists. A convergent synthetic route allowed for rapid SAR investigation and provided a diverse set of fused 6,5-heteroaryl analogs. Two potent and selective α7 nAChR partial agonists, (1′S,3′R,4′S)-N-(7-bromopyrrolo[2,1-f ][1,2,4]triazin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine (20) and (1′S,3′R,4′S)-N-(7-chloropyrrolo[2,1-f ][1,2,4]triazin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine (21), were identified. Both agonists improved cognition in a preclinical rodent model of learning and memory. Additionally, 5-HT3A receptor SAR suggested the presence of a steric site that when engaged led to significant loss of affinity at that receptor.